1. Scrip
  2. >>Drug Pricing

Semaglutide In 2027 Medicare Price Negotiations; Most Other Drugs Lose Exclusivity By Then

15 Products Totaled $41bn In Annual Part D Spending

 
• By Mandy Jackson

Novo took the biggest stock price hit of all the drug makers with products subject to Medicare price negotiations in 2027 under the IRA, but at least 11 of its peers on the list will be subject to generic competition between 2025 and 2027.

15 drugs that cost Medicare Part D $41bn in one year are slated for negotiated pricing in 2027 (Shutterstock)

Novo Nordisk’s blockbuster semaglutide franchise – Rybelsus and Ozempic for type 2 diabetes and Wegovy for obesity – was included in the Centers for Medicare and Medicaid Services (CMS) list of 15 drugs that will be subject to Medicare Part D negotiations for pricing effective in 2027 under the Inflation Reduction Act (IRA). The news was a shock to investors, despite plenty of speculation ahead of the CMS list reveal on 17 January that semaglutide products would be included. It remains to be seen if that is just for Wegovy’s cardiac health indication or the obesity indication, as there are efforts to allow Medicare to cover obesity medications.

Reduced pricing under Medicare Part D starting in 2027 may be a moot point for most of the other 14 drugs on the list, since at least 11 of those...

Stock Market Reactions

US closing stock prices and percentage changes on 17 January:

Novo Nordisk – $78.69, -5.3%

Ironwood – $3.66, -3.2%

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

More from Strategy

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.